DSpace Kyoto University
Japanese | English 

Kyoto University Research Information Repository >
Graduate School of Medicine >
Journal Articles  >

Please use this identifier to cite or link to this item: http://hdl.handle.net/2433/163079

Full text link:

File Description SizeFormat
j.ejphar.2012.09.010.pdf2.52 MBAdobe PDFView/Open
Title: Involvement of autophagy in the pharmacological effects of the mTOR inhibitor everolimus in acute kidney injury.
Authors: Nakagawa, Shunsaku
Nishihara, Kumiko
Inui, Ken-Ichi
Masuda, Satohiro
Author's alias: 増田, 智先
Keywords: Mammalian target of rapamycin
Autophagy
Proximal tubule
Acute kidney injury
Biomarker
Issue Date: 5-Dec-2012
Publisher: Elsevier B.V.
Journal title: European journal of pharmacology
Volume: 696
Issue: 1-3
Start page: 143
End page: 154
DOI: 10.1016/j.ejphar.2012.09.010
Abstract: Inhibitors of mammalian target of rapamycin (mTOR) have immunosuppressive and anti-cancer effects, but their effects on the progression of kidney disease are not fully understood. Using cells from normal kidney epithelial cell lines, we found that the antiproliferative effects of mTOR inhibitor everolimus accompanied the accumulation of a marker for cellular autophagic activity, the phosphatidylethanolamine-conjugated form of microtubule-associated protein 1 light chain 3 (LC3-II) in cells. We also showed that the primary autophagy factor UNC-51-like kinase 1 was involved in the antiproliferative effects of everolimus. Levels of LC3-II decreased in the kidneys of rats treated with ischemia-reperfusion or cisplatin; however, renal LC3-II levels increased after administration of everolimus to rats subjected to ischemia-reperfusion or cisplatin treatment. Simultaneously, increased signals for kidney injury molecule-1 and single-stranded DNA and decreased signals for Ki-67 in the proximal tubules were observed after treatment with everolimus, indicating that everolimus diminished renal function after acute tubular injury. We also found leakage of LC3 protein into rat urine after treatment with everolimus, and urinary LC3 protein was successfully measured between 0.1 and 500ng/mL by using an enzyme-linked immunosorbent assay. Urinary LC3 levels were increased after administration of everolimus to rats subjected to ischemia-reperfusion or cisplatin treatment, suggesting that renal LC3-II and urinary LC3 protein are new biomarkers for autophagy in acute kidney injury. Taken together, our results demonstrated that the induction of autophagy by everolimus aggravates tubular dysfunction during recovery from kidney injury.
Rights: © 2012 Elsevier B.V.
URI: http://hdl.handle.net/2433/163079
PubMed ID: 23022334
Appears in Collections:Journal Articles


Export to RefWorks

Access count of this item: 139

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

DSpace Software Copyright © 2002-2007 MIT and Hewlett-Packard - Feedback - Privacy policy